CoolSculpting the Upper Arm Study
- Conditions
- Body Fat Disorder
- Interventions
- Device: CoolSculpting device with vacuum applicator.
- Registration Number
- NCT02669329
- Lead Sponsor
- Zeltiq Aesthetics
- Brief Summary
Evaluate the safety and efficacy of the ZELTIQ CoolSculpting System using a specialized surface applicator for non-invasive subcutaneous fat reduction in the upper arm.
- Detailed Description
This multi-center trial will evaluate the Zeltiq CoolSculpting treatment to perform treatments in the upper arm for the reduction subcutaneous fat reduction.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Upper arm treatment with vacuum applicator CoolSculpting device with vacuum applicator. Subjects with clearly visible fat sufficient for treatment received bilateral CoolSculpting treatments, 1 treatment on each arm.
- Primary Outcome Measures
Name Time Method Percentage of Pre-treatment Images Correctly Identified 12 weeks post treatment Change in the treated vs. untreated areas will be assessed by observation of changes in surface contour and/or fat volume by an independent photo review of pre-treatment and post-treatment images of the treated areas. The review panel will consist of practicing dermatologists or plastic surgeons. All reviewers will be blinded to post-treatment vs. baseline untreated area. The order in which images will be presented will be randomized; for each subject placement of the baseline, pre-treatment image will be randomized for each pair of subject images. Reviewers will be asked to select the baseline photos for each subject photo series and record selections on a data collection form. Correct identification of photos by at least 2 of the 3 reviewers has an expected success rate of 75%.
Safety of the CoolSculpting Device in Upper Arm Treatments 12 weeks post-treatment The incidence of reported unanticipated adverse device effects (UADE) from the time of enrollment through the 12-week follow-up visit will be collected and analyzed. It is expected there will be zero UADE's reported.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Pacific Dermaesthetics
🇨🇦Vancouver, British Columbia, Canada
Dr. Jean Carruthers Cosmetic Surgery Inc.
🇨🇦Vancouver, British Columbia, Canada